| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biophys J, July 2000, p. 260-270, Vol. 79, No. 1
Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| |
ABSTRACT |
|---|
|
|
|---|
We have recently identified farnesol, an intermediate in the mevalonate pathway, as a potent endogenous modulator and blocker of N-type calcium channels (Roullet, J. B., R. L. Spaetgens, T. Burlingame, and G. W. Zamponi. 1999. J. Biol. Chem. 274:25439-25446). Here, we investigate the action of structurally related compounds on various types of voltage-dependent Ca2+ channels transiently expressed in human embryonic kidney cells. 1-Dodecanol, despite sharing the 12-carbon backbone and headgroup of farnesol, exhibited a significantly lower blocking affinity for N-type Ca2+ channels. Among several additional 12-carbon compounds tested, dodecylamine (DDA) mediated the highest affinity inhibition of N-type channels, indicating that the functional headgroup is a critical determinant of blocking affinity. This inhibition was concentration-dependent and relatively non-discriminatory among N-, L-, P/Q-, and R-Ca2+ channel subtypes. However, whereas L-type channels exhibited predominantly resting channel block, the non-L-type isoforms showed substantial rapid open channel block manifested by a speeding of the apparent time course of current decay and block of the inactivated state. Consistent with these findings, we observed significant frequency-dependence of block and dependence on external Ba2+ concentration for N-type, but not L-type, channels. We also systematically investigated the drug structural requirements for N-type channel inhibition. Blocking affinity varied with carbon chain length and showed a clear maximum at C12 and C13, with shorter and longer molecules producing progressively weaker peak current block. Overall, our data indicate that aliphatic monoamines may constitute a novel class of potent inhibitors of voltage-dependent Ca2+ channels, with block being governed by rigid structural requirements and channel-specific state dependencies.
| |
INTRODUCTION |
|---|
|
|
|---|
Calcium entry through voltage-gated channels
mediates a variety of physiological responses such as muscle
contraction, control of pacemaker activity, neurotransmitter release,
activation of Ca2+-dependent proteins, and
induction of gene transcription (e.g., McCleskey, 1994
; Dickson et al.,
1997
; Lemos and Nowycky, 1989
; Higuchi et al., 1996
). Consequently,
Ca2+ channels are important pharmacological
targets in designing treatments for cardiac arrhythmias, stroke,
migraine, cerebellar ataxia, and some forms of epilepsy (e.g., Camm et
al., 1991
; Ophoff et al., 1996
; Fletcher et al., 1996
). Thus, it is of
importance to understand the molecular determinants governing the
interactions between drugs and the channel protein, and it is desirable
to identify novel classes of compounds that interact with these channels.
Neuronal Ca2+ channels are heteromultimers of
1,
2,
, and
subunits. The
1 subunit, consisting of four
repeat domains of six transmembrane helices and a P-loop, provides the
pore, voltage sensor, and inactivation machinery of the channel
(Catterall, 1991
). To date, as many as 10
1
subunit genes have been identified, which are classified into the low
voltage-activated (LVA) T-type channels and the high voltage-activated
(HVA) N-, L-, P-, Q-, and R-types based on diverse biophysical and
pharmacological properties (for review, see Tsien et al., 1991
; Zhang
et al., 1993
).
1C,
1D,
1F, and
1S encode L-type Ca2+
channels (Tomlinson et al., 1993
; Williams et al., 1992b
; Bech-Hansen et al., 1998
; Ellis et al., 1988
),
1A makes
P/Q-type channels through alternative splicing (Bourinet et al., 1999
),
1B gives rise to N-type channels (Williams et
al., 1992a
),
1E is a unique type with
characteristics common to both LVA and HVA channels (Williams et al.,
1994
), and
1G,
1H,
and
1I encode T-type
Ca2+ channels (Perez-Reyes et al., 1998
; Cribbs
et al., 1998
; Lee et al., 1999
). The
1 subunit
is the target for most of the known Ca2+ channel
blockers (for review, see Zamponi, 1997
), and the particular pharmacological profile is frequently used as a key characteristic to
help identify a given Ca2+ channel subtype. For
example,
-conotoxins GVIA and MVIIA are specific for the
1B subunit (e.g., Boland et al., 1994
; Fox, 1995
),
-agatoxin IVA is selective for
1A
(e.g., Mintz et al., 1992
), and dihydropyridines are specific blockers
of the L-type isoforms (e.g., Bangalore et al., 1994
). In addition,
there are many types of far less selective Ca2+
channel blockers that may reflect the overall degree of homology among
individual Ca2+ channel subtypes (i.e., Zamponi,
1997
).
Recently, we have shown that farnesol, an intermediate of the
mevalonate pathway, mediates both a selective high affinity (100 nM)
inhibition of inactivated
1B channels and a
non-selective lower affinity (5-10 µM) resting/open channel block of
all types of HVA channels (Roullet et al., 1999
). Here, we examine the
action of a series of commercially available farnesol analogs on
Ca2+ channels transiently expressed in human
embryonic kidney (HEK) cells. Among several 12 carbon chain molecules
tested, dodecylamine (DDA) was identified as a highly potent inhibitor
of HVA channels. Qualitatively similar to farnesol, DDA caused a
nonselective peak current inhibition of all types of
Ca2+ channels tested, with block of the L-type
channels differing from that of non-L-type isoforms in its
state-dependence, use-dependence, and dependence on the external
permeant ion concentration. Experiments with a series of additional
aliphatic monoamines differing only in carbon chain length revealed
strict drug structural requirements for N-type channel inhibition, with
maximum inhibition occurring at a chain length of 13 carbons. Overall,
our data show that remarkably simple small organic molecules may have
the propensity to potently inhibit neuronal calcium channels.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials
Rat brain cDNAs coding for
1A,
1B,
1C,
1E, and
2-
were
donated by Dr. T. P. Snutch (University of British Columbia). The
following compounds were obtained from Sigma (St. Louis, MO): n-nonylamine, n-decylamine, DDA, n-dodecane; Aldrich (Milwaukee, WI):
tridecylamine, 1-tetradecylamine, pentadecylamine, 1-hexadecylamine, octadecylamine, 1-dodecanol, 4-dodecylphenol (mixture of isomers), dodecylacetate; and Acros (New Jersey, NJ): n-undecylamine. Drugs were
stored as 100 mM stock solutions in 100% ethanol and diluted into the
appropriate external recording solutions at the final concentrations
necessary. The final ethanol concentrations in the drug solutions
(
0.01%), when tested alone, have previously been shown to have no
effect on calcium channel currents (Roullet et al., 1999
).
Cell culture and transient transfection of HEK cells
HEK tSA 201 cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum, 200 U/ml
penicillin, and 0.2 mg/ml streptomycin at 37°C with 5%
CO2. At 85% confluency, cells were split with
0.25% trypsin-1 mM EDTA and plated at 10% confluency on glass
coverslips. At 12 h, medium was replaced and cells were
transiently transfected, using a standard calcium phosphate protocol,
with cDNAs encoding calcium channel
1,
2-
, and
1b
subunits and green fluorescent protein (EGFP, Clontech) at a 3:3:3:2
ratio. Fresh DMEM was supplied and cells were moved to 28°C, 5%
CO2 at 12 and 24 h after transfection, respectively. Cells were stored 1-2 days before recording. All tissue
culture reagents were obtained from Life Technologies, Inc. (Grand
Island, NY).
Electrophysiological recordings and analysis
Voltage-clamp data acquired using pClamp version 6.0.3 software
(Axon Instruments, Foster City, CA) were filtered at 1 kHz via an
Axopatch 200B amplifier (Axon Instruments) and stored on an
IBM-compatible PC. Borosilicate glass patch pipettes (Sutter Instrument
Co., Novato, CA) were polished (Microforge, Narishige, Japan) to a
resistance of ~4 M
when filled with cesium methanesulfonate internal solution (composition in mM: 109 CsCH3SO4, 4 MgCl2, 9 EGTA, 9 HEPES, pH 7.2). Cells were
bathed in external solution containing either 20 mM
BaCl2, 1 mM MgCl2, 10 mM
HEPES, 40 mM tetraethylammonium chloride, 10 mM glucose, 65 mM CsCl (pH
7.2) or 2 mM BaCl2, 1 mM
MgCl2, 10 mM HEPES, 40 mM tetraethylammonium chloride, 10 mM glucose, 105 mM CsCl (pH 7.2). Unless stated otherwise, current data shown were elicited by a 0.066 Hz train of 100-ms test
pulses from
100 mV to various potentials (min.
20 mV, max. +30 mV).
Drugs were perfused directly into the vicinity of the cells using a
home-built microperfusion system capable of solution exchanges in less
than one second.
Data were analyzed using Clampfit 6.0 (Axon Instruments). The time
constant of current decay was measured at various DDA concentrations by
exponential fits to the raw data. The control decay rate was fit with a
single exponential with time constant
h, while
currents in the presence of DDA were fit with a double exponential with one of the time constants fixed at the control
h value. The inverse of
was then plotted
as a function of DDA concentration. Assuming a 1:1 open channel
blocking interaction, 1/
= [D]kon + koff, where [D] is the drug
concentration and kon and
koff are, respectively, the blocking
and unblocking rate constants.
Normalized dose-response curves were fit (SigmaPlot 4.0, SPSS Inc.,
Chicago, IL) by the Hill equation to determine
IC50 values. Steady-state inactivation curves
were plotted as the normalized test pulse amplitude following 5-s
inactivating prepulses in 10-mV increments. Inactivation curves were
fit (SigmaPlot 4.0) with the Boltzmann equation,
Ipeak (normalized) = 1/(1 + exp((V
Vh)z/25.6)), where
V and Vh are the
conditioning and half-inactivation potentials, respectively, and
z is the slope factor. All error bars show standard error of
the mean; any numbers in parentheses shown in a figure reflect the
numbers of experiments, and p values reflect paired or
Student's t-tests.
| |
RESULTS |
|---|
|
|
|---|
An amine headgroup enhances N-type calcium channel block by linear C12 compounds
We have previously shown that farnesol mediates a high affinity
modulation of inactivated N-type calcium channels and a lower affinity
non-selective block of all types of neuronal HVA calcium channels
(Roullet et al., 1999
). To elucidate some of the underlying drug
structural requirements, we examined the effects of several commercially available farnesol derivatives on transiently expressed N-type calcium channels (bathed in 20 mM Ba2+),
and compared them to those previously observed with farnesol. Like
farnesol, 1-dodecanol (see Fig. 1)
exhibits a C12 hydrocarbon chain backbone and an alcohol group;
however, the double bonds and three methyl groups of farnesol are
lacking. At a concentration of 10 µM and a holding potential of
100
mV, 1-dodecanol caused a 14 ± 2% inhibition of peak current
amplitude of N-type calcium channels. This was significantly lower than
that observed with farnesol (38 ± 4%), indicating that either
the more rigid double bonds or the added hydrophobicity associated with
the three methyl groups in farnesol serve to enhance blocking affinity.
To examine a putative role of the alcohol group for calcium channel
block, we then varied the functional group attached to the dodecyl
backbone (see Fig. 1). Whereas 10 µM n-dodecane, 4-dodecylphenol, and
dodecylacetate failed to produce more than about a 15% inhibition of
peak current amplitude, application of 10 µM DDA virtually completely
(97 ± 1%) eliminated the N-type currents (Fig. 1 B).
Thus, the addition of an amine headgroup to the dodecyl backbone
structure mediated an almost 30-fold increase in blocking affinity,
well exceeding that observed originally with farnesol. These data
indicate that the functional group attached to the dodecyl backbone is
a critical determinant of blocking affinity, and that aliphatic
monoamines have the propensity to potently block voltage-dependent
calcium channels. To further characterize the action of DDA, and to
test whether the basic blocking properties previously observed with farnesol were preserved with the structurally simpler DDA, we carried
out a detailed characterization of DDA block on four different types of
high voltage-activated calcium channels.
|
DDA mediates both resting and open channel block
In order to test for a putative calcium channel isoform
selectivity of DDA block,
1A,
1B,
1C, and
1E channels (coexpressed with
1b and
2-
in
tSA-201 cells) were exposed to various concentrations of DDA. Fig.
2 A shows representative
current traces for each of the channel subtypes bathed in 20 mM
Ba2+. In all cases, DDA induced a reversible
reduction in peak current amplitude, with
1C
exhibiting the most pronounced inhibition as evident by comparing the
effect of 3 µM DDA on the current traces. This is also reflected in
the dose-response curves depicted in Fig. 2 B. The
IC50 values obtained from the fits were,
respectively, 0.8 µM, 1.8 µM, 2.0 µM, and 2.1 µM for
1C,
1B,
1E, and
1A, indicating a two to threefold higher affinity for L-type compared to
non-L-type channels, but overall a poor selectivity among individual calcium channel subtypes. For all channel types examined, the inhibition of peak current amplitude exhibited little if any detectable dependence on test potential (not shown).
|
Similar to what we had previously observed with farnesol, DDA mediated
a speeding of the apparent time course of inactivation. If DDA binding
simply speeds inactivation of the channel, the drug-bound channels
would inactivate with the faster rate, whereas the non-bound channels
would inactivate normally, thus yielding a double-exponential
macroscopic decay rate. With increasing drug concentrations, the
proportion of the drug-bound channels, and thus the contributions of
the faster inactivation time constants to the overall inactivation
rate, would increase, but the absolute values of the two time constants
should remain independent of DDA concentration. In contrast, if the
speeding were due to open channel block developing during the test
depolarization, the rate of development of block, and thus the
DDA-induced second time constant, would be expected to depend inversely
on DDA concentration. To discriminate between these two alternatives,
the time course of current decay in the presence of various DDA
concentrations was fit with two exponentials (
and
h), where
h was fixed
at the value obtained in the absence of DDA (see Methods). As seen from
Fig. 2 C, the inverse of the DDA-induced second time
constant (
) increased linearly with DDA concentration, consistent
with the open channel blocking model and our previous observations with
farnesol (Roullet et al., 1999
). In this scenario, the slope and
y-intercept of the regression line would reflect the
blocking and unblocking rate constants, respectively (see Methods). As seen from Fig. 2 C, block of the three non L-type channels
occurred with similar kinetics, whereas L-type channels exhibited about twofold slower blocking and unblocking rate constants. Overall, these data may indicate that the open channel blocking site is highly
conserved across different types of voltage-dependent calcium channels.
For each of the channels examined, open channel block could account for
only part of the overall inhibition observed at the time of peak, thus
suggesting the presence of an additional tonic (i.e., resting channel)
blocking component. Among the four channel types examined, the L-type
isoform was subject to the largest contribution from resting block,
which could account for nearly 90% of the peak current reduction
observed in the presence of 1 µM DDA. A substantial contribution from
resting channel block was also observed with
1B, which contrasts with our previous observations with farnesol, where the peak current inhibition of
1B could be attributed almost exclusively to
open channel block developing during the activation phase (Roullet et
al., 1999
). In contrast, the inhibition seen at the end of the test depolarization is predominantly due to open channel block, with some
contribution from the initial tonic block.
The kinetic analysis depicted in Fig. 2 C suggests that
after drug equilibration, block and unblock of the channels occurs in
the range of milliseconds. This contrasts with the much slower time course of development of, and recovery from, peak current inhibition of
1B evident in Fig. 2
D, which occurred over the course of one to two minutes.
Thus, similar to what we had observed, with farnesol, DDA block of HVA
calcium channels appears to involve a rate-limiting step other than the
true interaction rates between the blocker and the channel, such as
partitioning into the plasma membrane.
DDA mediates inactivated channel block of non-L-type channels
One of our key observations with farnesol was a selective
inhibition of inactivated N-type calcium channels (Roullet et al., 1999
) demonstrated by a farnesol-mediated shift in half-inactivation potential. To test whether DDA could mediate a similar inhibition, we
investigated the effect of 1 µM DDA on the position of the steady-state inactivation curves of the four types of calcium channels
with 20 mM barium as the external charge carrier. As evident from Fig.
3, DDA mediated a 10-15-mV shift in
half-inactivation potential for all of the non-L-type channels tested.
Thus, unlike farnesol, inactivated channel block by DDA is not
exclusive to N-type calcium channels. These observations might indicate
that the double bonds and/or the additional methyl side chains of
farnesol (see Fig. 1) could contribute to the N-type channel
selectivity of inactivated channel block. Whereas the shifts in
half-inactivation potential observed with non-L-type channels do not
significantly affect peak current levels at hyperpolarized holding
potentials (i.e.,
100 mV, such as in Fig. 2), at a typical neuronal
resting potential (i.e.,
70 mV), these shifts in the midpoint of the steady-state inactivation curve would result in further depression of
peak current amplitude in addition to that mediated by open and resting
channel block. In contrast with non-L-type channels, application of 1 µM DDA did not significantly affect the position of the steady-state
inactivation curve of
1C, indicating that L-type channels do not undergo inactivated channel block.
|
We also tested the effects of 1-dodecanol on the steady-state
inactivation of
1B. As in the case of DDA, a
12 mV negative shift in half-inactivation potential was observed (not
shown), however, only at 10-fold higher concentrations (10 µM),
whereas application of 1 µM 1-dodecanol was ineffective. Together
with our previous observation with farnesol, where a shift of similar magnitude was observed at concentrations as low as 100 nM (Roullet et
al., 1999
), these data indicate that the functional group on the
dodecyl backbone and the actual backbone structure contribute to the
affinity for the inactivated state of N-type channels.
DDA block of L-type and N-type channels differs in its use-dependence
From the observation that L-type calcium channels predominantly
exhibit resting channel block, whereas the non-L-type isoforms also
show substantial inactivated and open channel block, one might predict
a selective use-dependence of DDA action on non-L-type channels. Under
control conditions with
1B or
1C (open symbols, Fig.
4, C and D),
increasing the pulse frequency mediated only a small (<5%) degree of
current inhibition, indicating that little inactivation accumulates in
the absence of DDA even at the highest pulse frequency (2 Hz) used.
Fig. 4, A and B depict the effect of a 2 Hz
stimulation on current levels before (left traces) and after
complete (2 min) equilibration (right traces) with DDA. Under those conditions, the first test pulse in the train after drug
equilibration reveals tonic peak current block of, respectively, 20 ± 5% and 48 ± 6% for
1B and
1C. As the train continues, significant use-dependent block develops for
1B, but not
for
1C. This can be seen upon comparison of
the current levels obtained during the 1st, 10th, and 20th pulses in
the train and is further illustrated in Fig. 4, C and
D for a series of different pulse train frequencies. As
evident from the figure,
1B, but not
1C, channels accumulated a significant
additional block at 1 and 2 Hz stimulus rates compared with slower
rates of stimulation. Fig. 4, E and F compare
total peak current amplitude inhibition by DDA in the 2 Hz pulse
protocol and the original (0.066 Hz) step protocol used in Fig. 2
B. Besides the open channel and tonic blocking components
described earlier, higher frequency stimulation produced an additional
20% block of
1B channels, whereas
1C channels were not significantly affected. The lack of use-dependence observed with
1C is
consistent with the idea that these channels undergo predominantly
resting channel block. Overall, our data further support the notion
that L-type channel block by DDA differs from that of non-L-type
channels in its state-dependence.
|
DDA block of L-type and N-type channels differs in its sensitivity to [Ba]o
We have previously hypothesized that open channel block by
farnesol might occur via physical occlusion of the pore (Roullet et
al., 1999
). One feature frequently associated with pore block is a
dependence of blocking affinity on the concentration of external carrier ion. To test whether such a characteristic could be observed with DDA, we reduced the concentration of external permeant ion from 20 mM to 2 mM and assessed the change in blocking affinity for N-type and
L-type channels. Fig. 5, A and
B depict the effects of DDA in the form of representative
current traces obtained in 20 mM (from Fig. 2 A) and 2 mM
external barium solutions. For
1B, the degree
of peak current inhibition by DDA was dramatically enhanced in 2 mM
barium. Furthermore, in lower external saline, the speeding of the time
course of current decay was observed at lower DDA concentrations,
consistent with our interpretation that the enhanced decay rate in the
presence of DDA reflected open channel block. Analysis of the rate of
current decay in 2 mM barium solution revealed a 52% increase in the
association rate constant (kon) and a
12% decrease in the dissociation rate constant
(koff) compared to 20 mM barium,
indicating a slightly less than twofold increase in blocking affinity
in lower external barium solution. In contrast,
1C currents actually underwent, if anything, a
slight decrease in blocking affinity when external barium was reduced
to 2 mM. This is further illustrated in form of dose-response curves
(Fig. 5, C and D) for peak current inhibition. Whereas reduction of external charge carrier concentration had little
effect on
1C channels, the
IC50 for DDA block of
1B
was decreased approximately fivefold. In view of the relatively
moderate effects of charge carrier concentration on the open channel
blocking affinity, the larger effect observed with the dose-dependence of peak current inhibition of
1B channels may
suggest that both open and resting channel block were affected, which
cannot easily be explained by a simple competition between barium ions
and DDA within the permeation pathway. Thus, there appears to be a
fundamental difference in the detailed mechanism by which DDA mediates
peak current block of N-type and L-type channels. Finally, of
particular note, with an IC50 of ~400 nM in 2 mM Ba2+, DDA is among the most potent small
organic inhibitors of N-type channel activity described to date, which
is remarkable in view of the structural simplicity of the compound.
|
Blocking affinity for N-type channels depends on hydrocarbon chain length
To examine whether block of N-type calcium channels by aliphatic
monoamines might be dependent on the length of the hydrocarbon backbone, we systematically varied the backbone chain length while keeping the functional amine headgroup constant. Eight additional commercially available aliphatic monoamines ranging in chain length from 9 to 18 carbons were tested on N-type calcium channels bathed in
20 mM barium saline at a holding potential of
100 mV. Fig. 6 illustrates peak current block by each
of these compounds at a concentration of 10 µM. A pattern of chain
length-dependence is readily observable. C12 (DDA) and C13
(tridecylamine) abolished virtually all of the current. With decreasing
hydrocarbon chain length, blocking affinity became progressively
reduced from 73 ± 7% block (C11) to 21 ± 3% block (C9).
Likewise, as chain length was increased, the degree of N-type channel
block decreased monotonically to 7 ± 3% for C18. Overall, it
appears as if a chain length of 12 or 13 carbons yields optimum
conditions for N-type channel block. Thus, the three-dimensional makeup
of the drug binding site on the N-type calcium channel molecule appears
to place strict physical constraints on the size of drug molecule it
can accommodate, which in turn may provide insights into the pore
structure.
|
| |
DISCUSSION |
|---|
|
|
|---|
Comparison with farnesol block
In our previous study on farnesol, we demonstrated that farnesol
caused two types of inhibition of voltage-dependent calcium channels: a
low affinity inhibition that showed a slight preference for L-type
channels, but was nonetheless relatively nonselective for different
types of HVA channels, and a higher affinity inactivated channel block
that was selective for N-type channels (Roullet et al., 1999
). There
are three major structural differences between DDA and farnesol (see
Fig. 1), as DDA lacks the three double bonds and methyl groups in the
backbone, and the terminal -OH group of farnesol is replaced by an
amine. It is perhaps not surprising to note that DDA action differed
from that of farnesol in several ways. First, DDA block (at a holding
potentials of
100 mV) occurred with 10-fold higher affinity. Second,
while this type of inhibition retained a slight preference for L-type
channels, the contribution of resting channel block to the overall peak
current block seen with non-L-type channels was much greater than that
observed with farnesol. Third, whereas the ability to block inactivated
N-type channels was retained in DDA, its selectivity for N-type
channels was lost.
Despite these differences, several qualitative features of farnesol
block were also seen with DDA. For example, DDA block of L-type and
non-L-type channels differed in its state-dependence. Like farnesol,
DDA has the general ability to interact with multiple kinetic states of
the channel. Finally, both farnesol and DDA accelerated the rate of
current decay and showed an increase in blocking affinity in lower
concentrations of external barium in a manner consistent with an open
channel blocking mechanism (Roullet et al., 1999
). Nonetheless, whereas
the general blocking mechanisms of farnesol are retained in the
structurally much more rudimentary DDA molecule, many of the detailed
aspects of calcium channel block by these two molecules appear quite distinct.
Effect of DDA on other membrane proteins
A wide diversity of biological actions of DDA have been reported
in the literature, ranging from enhancement of skin permeation for drug
delivery (Aungst et al., 1990
) to inhibition of osmotic-sensitive calcium influx in bacteria (Beeler et al., 1997
). However, DDA is
perhaps best known as an inhibitor of the cardiac sodium/calcium exchanger. Philipson (1984)
demonstrated ~60% inhibition of
Na+-dependent Ca2+ uptake
by the canine cardiac
Na+/Ca2+ exchanger with 20 µM DDA, while a Ki of 3 µM has been reported for DDA inhibition of frog atrial "creep" currents, the
electrogenic current generated by
Na+/Ca2+ exchange
(Bielefeld et al., 1986
). Consistent with our data on L-type channels
(IC50 ~ 0.8 µM), Bielefeld reported that
blocking affinity for myocardial L-type calcium and potassium currents occurred within the same range as block of exchange activity. In
contrast, Terrar and White (1989)
argued that DDA effects on cardiac
calcium channels were only minimal compared to inhibition of
Na+/Ca2+ exchange. Our
results obtained with N-type channels in 2 mM external barium
(IC50 of 400 nM), together with the added
inactivated channel block that would be present at a typical neuronal
resting membrane potential, suggest that calcium channels may be much
more sensitive to DDA than other ion transport molecules. Nonetheless,
the observation that DDA is capable of inhibiting multiple types of
cation transport proteins might reflect a common blocking mechanism.
Based on the dependence of blocking affinity on external carrier ion
concentration, one likely site of action of DDA is in the channel pore.
Many types of cation channels share a similar P-loop motif, thus
providing ample opportunity for conserved structures that may form the
receptor site for DDA and related compounds. Consistent with such a
mechanism, a number of monoamines have been shown to block inward
rectifier potassium channels (Pearson and Nichols, 1998
), and several
of the structurally related quaternary ammonium compounds are potent pore blockers of voltage-dependent sodium channels (Wang et al., 1991
).
Drug-structural requirements for N-type channel block
Several hydrocarbon molecules with different functional headgroups
have been shown to block calcium channels. For example, acidic omega-3
fatty acids (Leaf, 1995
) have been reported to potently inhibit L-type
calcium channels. In addition, compounds such as farnesol (Roullet et
al., 1999
) and aliphatic alcohols (Hawthorn et al., 1992
) block calcium
channels at micromolar concentrations. Therefore, one might expect the
functional group to be relatively unimportant. Our finding that
1-dodecanol, n-dodecane, 4-dodecylphenol, and dodecylacetate show
~15% block at 10 µM would have been consistent with this idea.
However, addition of a terminal amine (as in DDA) resulted in an almost
30-fold increase in blocking affinity compared with these other
compounds. Thus, the functional group can be a major determinant of
blocking efficacy of aliphatic monoamines. Additional structural
derivatives will ultimately need to be examined to assess whether the
addition of an amine group can generally enhance the blocking affinity
of carbon chain molecules for calcium channels.
When comparing the effects of 1-dodecanol, DDA, and farnesol on steady-state inactivation of N-type channels, we can draw two conclusions. Compared with DDA, 1-dodecanol required 10-fold higher concentrations to mediate the same shift in half-inactivation potential, suggesting that the functional group contributes to the affinity for inactivated channels. Furthermore, farnesol, which carries the same functional group as 1-dodecanol, was 100-fold more effective in shifting the half-inactivation potential, strongly suggesting that the nature of the backbone structure is also critical for inactivated channel block.
We also observed a very sharp dependence of blocking affinity on
hydrocarbon chain length for a series of aliphatic monoamines, with C12
and C13 compounds being most effective. While we cannot completely rule
out the possibility that the longer molecules show a reduced degree of
solubility, the reduced affinity seen with the longer compounds could
also indicate that the blockers become too large to be properly
accommodated by the binding site. Conversely, the lower blocking
affinity observed with the shorter compounds could reflect an inability
of these compounds to fully interact with all of the "microsites"
contained within the overall drug-binding pocket on the channel. The
dependence of blocking affinity on hydrocarbon chain length is not
unique to voltage-dependent calcium channels. Experiments on inward
rectifier K+ channels revealed voltage-dependent
block by monoamines that showed increasing potency and slower
unblocking rates as the chain length was progressively increased from
C5 to C12 (Pearson and Nichols, 1998
). For open channel block of
batrachotoxin-activated sodium channels by quaternary amines,
increasing the side chain length from 12 to 18 carbons mediated an
increase in mean blocked time (Wang et al., 1991
). Furthermore, the
authors identified a bell-shaped relation between blocking kinetics and
carbon chain length. Philipson (1984)
tested several aliphatic amines
ranging from C8 to C16 (including DDA) and showed a progressively
increasing potency for
Na+/Ca2+ exchange
inhibition. These data contrast with our finding that blocking affinity
decreases as alkylamine chain length is increased past C13 and further
differentiates the effects of alkylamines on
Na+/Ca2+ exchangers and
Ca2+ channels. This may argue against the
possibility that our observations with longer chain compounds are due
to a simple solubility effect.
Mechanism of DDA block
Based on the observation that open channel block by farnesol
seemed to require diffusion of the compound into the membrane phase, we
had suggested that farnesol might perhaps act as a pore blocker from
the cytoplasmic side of the channel (Roullet et al., 1999
). Unlike
farnesol, dodecylamine contains a tertiary amine with a
pKa of 10.6, and thus DDA is essentially
permanently charged at physiological pH and unavailable for crossing
the plasma membrane. In several experiments, we added 10 µM DDA to
the internal recording solution, and after 10 min of dialysis, we did
not detect any significant block of N-type channels (Beedle and
Zamponi, unpublished observations). Conversely, the rate constants for
open channel block are three orders of magnitude faster than that
required for equilibration of the drug, consistent with at least
partial entry into the membrane phase rather than a simple pore
occlusion mechanism from the external side of the channel. It is
possible that the blocking site could be accessible via a
membrane-delimited pathway similar to what has been proposed for
lidocaine block of batrachotoxin-activated sodium channels (Zamponi et
al., 1993a
, b
). If so, the terminal nitrogen moiety would remain
confined to the extracellular side, whereas the hydrophobic tail end
might access the actual blocking site. Such a mechanism could account for the observation that blocking affinity becomes reduced with decreasing carbon chain length and would space the drug binding site
~10-15 Å into the lipid bilayer from the external side. However, how can such a model account for the observation that 1-dodecanol was
only poorly effective in blocking N-type channel activity, despite
sharing an identical backbone with DDA and being able to freely
partition into the membrane phase? Clearly, the simple presence of the
charged amino group dramatically enhances blocking affinity, but does
not appear to be required for block (note that all of the compounds
displayed in Fig. 1 show qualitatively similar block). It is
conceivable that negative surface charges on the extracellular face of
the membrane and/or the channel may serve to increase the local
concentration of protonated DDA, thus resulting in an apparent increase
in blocking affinity. The less effective surface charge screening
associated with a reduction of the external divalent ion concentration
would result in additional DDA accumulation near the membrane, thus
providing a possible explanation for the higher DDA affinity for
1B channels in lower ionic strength saline. However, the notion that this did not occur with L-type channels would
argue against a diffuse membrane surface charge effect. Alternatively,
the amino group of DDA could bind to one or more specific residues on
the extracellular face of the channel protein, thereby facilitating the
interaction between the hydrophobic tail and the functional blocking
site on the channel. Ultimately, however, additional analogs such as
quaternary derivatives will need to be examined to further substantiate
our current hypothesis.
In summary, DDA is a remarkably simple compound capable of producing calcium channel block with submicromolar affinity. The observation that subtype specificity and blocking affinity of these carbon chain molecules can be dramatically altered with relatively small structural changes suggests that structural derivatives of this class of molecules may perhaps yield novel, high affinity blockers selective for certain types of voltage-dependent calcium channels.
| |
ACKNOWLEDGMENTS |
|---|
We thank Dr. Terry Snutch for providing calcium channel cDNAs and Dr. Z-P. Feng for helpful comments on the manuscript.
This work was supported by a grant to G.W.Z. from the Medical Research Council of Canada (MRC) and from the Heart and Stroke Foundation of Alberta and the Northwest Territories. G.W.Z. holds faculty scholarship awards from the MRC, the Alberta Heritage Foundation for Medical Research (AHFMR), and the EJLB Foundation. A.M.B. is the recipient of an AHFMR studentship award.
| |
FOOTNOTES |
|---|
Received for publication 5 January 2000 and in final form 21 March 2000.
Address reprint requests to Dr. Gerald W. Zamponi, Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. Tel.: 403-220-8687; Fax: 403-210-8106; E-mail: Zamponi{at}ucalgary.ca.
| |
REFERENCES |
|---|
|
|
|---|
-Conotoxin block of N-type calcium channels in frog and rat sympathetic neuron.
J. Neurosci.
14:5011-5027[Abstract].
1A subunit gene generates phenotypic variants of P- and Q-type calcium channels.
Nature Neurosci.
2:407-415.
1H from human heart, a member of the T-type calcium channel gene family.
Circ. Res.
83:103-109[Abstract/Full Text].
1 and
2 subunits of a DHP-sensitive calcium channel.
Science.
241:1661-1664[Medline].
-conopeptides.
Pfluegers Arch.
429:873-875[Medline].
-Aga IVA.
Nature.
355:827-829[Medline].
-conotoxin-sensitive human N-type calcium channel.
Science.
257:389-395[Medline].
1,
2, and
subunits of a novel human neuronal calcium channel subtype.
Neuron.
8:71-84[Medline].
1E calcium channel subtypes.
J. Biol. Chem.
269:22347-22357[Abstract].
Biophys J, July 2000, p. 260-270, Vol. 79, No. 1
© 2000 by the Biophysical Society 0006-3495/00/07/260/11 $2.00
This article has been cited by other articles:
![]() |
Z.-P. Feng, J. Hamid, C. Doering, G. M. Bosey, T. P. Snutch, and G. W. Zamponi Residue Gly1326 of the N-type Calcium Channel alpha 1B Subunit Controls Reversibility of omega -Conotoxin GVIA and MVIIA Block J. Biol. Chem., May 4, 2001; 276(19): 15728 - 15735. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |